3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
81
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Multiple Myeloma
4
HER2-positive Breast Cancer
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hematologic Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Wilms Tumor
1
Uterine Neoplasms
1
Urologic Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Thyroid Neoplasms
1
Thrombocytosis
1
Solid Tumors
1
Sarcoma, Synovial
1
Sarcoma
1
Interventions
sacubitril and valsartan sodium hydrate drug combination
3
Nutrition Assessment
3
Exercise
3
Carvedilol
3
dapagliflozin
2
Standard of Care
2
Rituximab
2
Ivabradine
2
Control Groups
2
Atorvastatin
2
pertuzumab
1
pegfilgrastim
1
obinutuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
acalabrutinib
1
Vincristine
1
Valsartan
1
Trastuzumab
1
Surveys and Questionnaires
1
Spironolactone
1
Sodium Chloride
1
Simendan
1
Secondary Prevention
1
Resistance Training
1
Pyruvic Acid
1
Prednisolone
1
Practice Guidelines as Topic
1
Population Groups
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Heart Failure
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled